Related Experiment Video
Updated: Dec 24, 2025
07:50
Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
Published on: September 18, 2020
6.0K
Epigenetic Biomarkers in Gallbladder Cancer
1Centre for Genomics, Jiwaji University, Gwalior 474011, Madhya Pradesh, India.
Trends in Cancer
|April 16, 2020
Summary
Epigenetic changes are emerging as promising diagnostic biomarkers for gallbladder cancer (GBC). These discoveries also offer potential new therapeutic targets for improving GBC treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Gallbladder cancer (GBC) presents significant diagnostic challenges due to a lack of specific and sensitive markers.
- This diagnostic gap contributes to high mortality rates associated with GBC.
- Both nongenetic and genetic factors are implicated in the development of GBC.
Purpose of the Study:
- To highlight recent advancements in identifying diagnostic biomarkers for GBC.
- To explore the potential of epigenetic alterations as novel biomarkers for GBC.
- To discuss the therapeutic implications of these epigenetic discoveries for GBC treatment.
Main Methods:
- Review of recent scientific literature on GBC.
- Analysis of studies focusing on epigenetic modifications in cancer.
- Identification of specific epigenetic changes associated with GBC.
Main Results:
- Epigenetic changes have been identified as potential diagnostic markers for GBC.
- These epigenetic alterations show promise for early detection and improved diagnosis.
- The discovered epigenetic markers may also serve as targets for future GBC therapies.
Conclusions:
- Epigenetic modifications represent a significant breakthrough in GBC diagnostics.
- Further research into these biomarkers could lead to improved patient outcomes.
- Targeting epigenetic pathways offers a new avenue for GBC therapeutic strategies.
